MedTrace Logo

A Randomized Trial of Rosuvastatin in Elective Angioplasty to Prevent Contrast-induced Nephropathy (CLEAR-CIN).

NCT02737319 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 493

Last updated 2016-04-14

No results posted yet for this study

Summary

The investigators analyzed the HMG-CoA reductase inhibitor, rosuvastatin, for the prevention of contrast-medium-induced nephropathy in patients undergoing primary angioplasty.

Conditions

  • Nephropathy

Interventions

DRUG

Rosuvastatin

40 mg of rosuvastatin before angioplasty

Sponsors & Collaborators

  • Instituto Dante Pazzanese de Cardiologia

    collaborator OTHER

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • Kleber Bomfim A Martins, MD, PhD · Instituto Date Pazzanese de Cardiologia

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02737319 on ClinicalTrials.gov